Mexican genomics institute plans incubator:
This article was originally published in Clinica
Executive Summary
Mexico's genomic institute, (Inmegen), is considering establishing a commercial incubator. This week, the institute received funding to launch a feasibility study for the project, which seeks to speed up the development of new technologies for use in the national health service, linked to the national bio- and medical technology industries. Inmegen is the result of an alliance involving the health ministry, the national science and technology council, the national autonomous university of Mexico (UNAM) and the Mexican healthcare foundation.
You may also be interested in...
How Ochre Bio Bagged Boehringer For Its RNA-Based Regenerative MASH Therapies
UK-based Ochre Bio has signed its first major deal with Boehringer Ingelheim. Scrip talked to its co-founder and CEO, Jack O’Meara, about its human tissue-based drug discovery platform, its resulting RNA platform for liver disease and how the fledgling drug company's early work mirrored that seen in diagnostics.
IGI Bets On Trispecific Antibody To Make Inroads Into Big Pharma Myeloma Turf
Ichnos Glenmark Innovation’s president and CEO talks to Scrip about the promising activity profile of the alliance’s early stage trispecific antibody versus Janssen’s teclistamab and also maintains that the setback for Gilead’s magrolimab hasn’t eclipsed prospects for its bispecific antibody.
UK Medtech Strategy Sets Out Schedule Of Milestones To FY 2026
Fourteen months on from the release of its inaugural medtech strategy, the UK MedTech Directorate has laid firm foundations and reports progress on initiatives aimed at improving technology adoption. A schedule of ambitious future timelines has also been published.